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EDITORIAL
Alport syndrome and thin basement membrane nephropathy:
Unraveling the tangled strands of type IV collagen
A trimer consisting of two a1 chains and one a2 chain
of type IV collagen ([a1]2[a2](IV)) is an essential compo-
nent of basement membranes including the subendothe-
lial layer of the glomerular basement membrane (GBM)
[1]. In contrast to the ubiquity of [a1]2[a2](IV), the a3, a4,
and a5 chains of type IV collagen are found in few specific
sites: the basement membranes of glomeruli and distal
tubules, neuromuscular junctions, eye, ear, lung, and sem-
iniferous tubules. [a1]2[a2](IV) is present at all stages of
development. During nephrogenesis, collagen a3, a4, and
a5 chains appear at the capillary loop stage of glomeru-
lar development [2], and the a3a4a5(IV) trimer progres-
sively replaces [a1]2[a2](IV) as the dominant constituent
of GBM collagen. Laminin, another major component of
the GBM, shows a similar ontogenetic transition from
laminin A,B1,B2 to A,S,B2 that parallels the switch from
[a1]2[a2](IV) to a3a4a5(IV) [3].
Mutations in any of the a3-5(IV) chains may impair
formation of the a3a4a5(IV) heterotrimer that forms
the major part of the lamina densa interna in postna-
tal life [4]. In Alport syndrome (AS), the GBM is ini-
tially uniformly thin, but then proteolysis and attempted
reconstruction with [a1]2[a2](IV) produce a thickened
and multilayered GBM. In thin basement membrane
nephropathy (TBMN), the ultrastructural appearance is
initially indistinguishable from Alport syndrome, but pro-
gressive disruption of the basement membrane, renal in-
sufficiency, and extrarenal manifestations do not occur.
The condition is common, and occurs in at least 1% of the
population.
The Melbourne group has previously shown that hema-
turia segregates with the COL4A3/COL4A4 locus on
chromosome 2 in up to 36% of families with TBMN [5].
Mutations in COL4A3 [6, 7] and COL4A4 [7, 8] can
cause autosomal-recessive Alport syndrome. In this is-
sue of Kidney International, Wang et al [9] describe a
systematic examination for mutations of the COL4A3
gene in 62 individuals with clinical or biopsy evidence
of thin glomerular basement membrane disease. Most of
the subjects had previously been examined for mutations
in COL4A4. This adds to the growing evidence yoking
mutations in these genes to TBMN [10–14].
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Heterozygosity for a COL4A3 or COL4A4 mutation
causes thin glomerular basement membrane disease, and
homozygosity or mixed heterozygosity causes autosomal-
recessive Alport syndrome [14]. This can be understood
as a “dose effect:” presence of one normal allele results
in less a3a4a5(IV) formation, absence of a normal al-
lele, and a lack of a3a4a5(IV). With loss of one allele,
the resulting lamina densa is thin, but seemingly resistant
to proteolysis. As might be expected, a mutation in each
of COL4A3 and COL4A4 has not turned out to be an
appreciable cause of Alport syndrome: one normal allele
of each chain remains. Occasional families with a single
COL4A3 or a COL4A4 mutation do develop renal fail-
ure, usually in adult life [11, 15, 16]. This may signify that
some mutations are more deleterious than others, or that
other modifying effects are involved. At first sight, these
cases of autosomal-dominant Alport syndrome might be
thought analogous to women heterozygous for X-linked
Alport syndrome, some of whom eventually develop re-
nal failure and extrarenal manifestations. The analogy is
not exact, however, because lyonization in females het-
erozygous for a COL4A5 mutation ensures that some mo-
saic domains possess, and others lack, normal a5 chains,
and thus, a3a4a5(IV), rather than there being an overall
quantitative reduction in a3a4a5(IV). Further research
is needed to extend the generality of these findings about
COL4A3 and COL4A4 mutations, and to identify other
hereditary abnormalities of the GBM.
The spectrum of hereditary type IV collagen
nephropathies thus spans from TBMD (COL4A3 or
COL4A4 heterozygotes), in which renal function typ-
ically declines no faster than the population mean, to
severe forms of AS, with renal failure in childhood
(COL4A5 male hemizygotes and COL4A3 and COL4A4
homozygotes or mixed heterozygotes). As is so common
in medicine, milder forms are more frequent, but more se-
vere forms attract more attention. Intermediate in sever-
ity are the adult forms of Alport syndrome. In the United
States these forms appear less frequent than TBMD but
more frequent than juvenile forms of AS. Adult-type Al-
port syndrome may remain undiagnosed because renal
failure occurs in adult life with little to distinguish it from
advanced glomerulonephritis. Diagnosis is particularly
treacherous because the largest family, with apparently
several thousand gene carriers, does not have prominent
hearing loss [17].
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A real conundrum for the pediatric nephrologist who
must give a prognosis to parents of children with hema-
turia is distinguishing TBMN from adult types of Alport
syndrome. Unless there is a clear family history of re-
nal failure, even biopsy and follow-up for several years
cannot distinguish between these two. Microhematuria is
not constantly present in TBMN [8], sporadic hematuria
in females can obscure the picture, and clinical pedigree
analysis rarely suffices to distinguish the mode of inheri-
tance with certainty. Confident reassurance about the be-
nign nature of the nephropathy may later prove cruelly
misplaced. We have encountered this tragedy in families
belatedly shown to have COL4A5 mutations or renal fail-
ure in the extended family. Misdiagnosis of Alport syn-
drome as TBMN may be quite common: 10% of families
with a biopsy diagnosis of TBMN showed linkage to the
COL4A5 locus, suggesting that they were really families
with Alport syndrome [5]. The ultimate solution to this
problem lies in genetic diagnosis, but at present this is not
readily available. Even if it were available, the currently
low detection rate for mutations would limit its useful-
ness. Right now, the best a practicing clinician can do is
take a detailed and persistent family history, particularly
looking for severely affected males on the mother’s side
of the family, and to bear in mind that a clinical and biopsy
diagnosis of TBMN is fallible unless the family contains
several examples of elderly hematuric males with normal
renal function.
If real suspicion arises concerning the possibility of an
adult type of Alport syndrome in a young person with
hematuria, or if a patient with hematuria in a family pu-
tatively affected with TBMN is being evaluated as a re-
nal donor, analysis for a C1564S or L1649R mutation in
COL4A5 is reasonable and available in the United States.
At present, more widespread screening for collagen IV
gene mutations does not appear justified.
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